New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
07:04 EDTEBSEmergent announces waiting period expiration for Cangene acquisition
Emergent BioSolutions announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with Emergentís proposed acquisition of Cangene has expired. The expiration of the waiting period for antitrust review of the proposed acquisition satisfies one of the conditions to the closing of the acquisition. As announced on December 11, 2013, Emergent and Cangene have entered into a definitive agreement under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222M. Completion of the acquisition is subject to approval by 66 2/3% of the votes cast by Cangene shareholders at a special shareholder meeting scheduled for February 12, approval by the Ontario Superior Court of Justice at a hearing scheduled for February 18 and other customary closing conditions. The transaction is expected to close before the end of1Q14.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 13, 2015
07:13 EDTEBSEmergent BioSolutions receives $44M CDC contract to advance VIGIV
Emergent BioSolutions announced that the Centers for Disease Control and Prevention, or CDC, has exercised options under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin into the U.S. Strategic National Stockpile. The contract options, valued at $44M over two years, will require Emergent to collect plasma for future manufacturing in addition to current collection requirements, conduct manufacturing runs, and conduct additional activities in support of maintaining the FDA licensure of VIGIV. This contract modification increases the total contract value to approximately $80M. The scope of the contract, originally awarded to Cangene Corporation, which Emergent acquired in February 2014, was to maintain the ability to manufacture licensed VIGIV, with annual options to conduct additional services to support licensure maintenance activities for the product and to allow for additional manufacturing and plasma collections. VIGIV was first delivered into the SNS in 2002 and was subsequently licensed in the U.S. by FDA in 2005 and in Canada by Health Canada in 2007.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use